Damora Therapeutics (DMRA) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 29 151 sessions, March 10, 2026 to October 13, 2026
- Largest daily move
- +27.1% close of March 23, 2026
- 1-month change
- -34% closing prices, September 11, 2026 to October 13, 2026
Company Description
Damora Therapeutics, Inc. develops biologic therapies for hematologic disorders, with a focus on mutant calreticulin-driven myeloproliferative neoplasms. The company’s programs address blood disorders including essential thrombocythemia and myelofibrosis, where its therapeutic work centers on disease-modifying biologics designed for patients with mutCALR-driven disease biology.
The company’s pipeline includes DMR-001 as its lead program, along with additional programs DMR-002 and DMR-003. These assets were added through the completed acquisition of privately held Damora Therapeutics in November 2025, which established the public company’s current development focus around mutCALR-targeted therapies for myeloproliferative neoplasms.
Damora operates as a biotechnology issuer rather than a diversified health-care products company. Its business model centers on research and development, regulatory preparation, and advancement of therapeutic candidates through the development pathway. Company communications describe a portfolio approach to biologics intended to cover the spectrum of patients with mutant calreticulin-driven myeloproliferative neoplasms.
Damora Therapeutics is incorporated in Delaware and lists its common stock on Nasdaq under the symbol DMRA. Regulatory records identify the company’s principal executive office in Waltham, Massachusetts. As a public biotechnology company, its recurring corporate disclosures include pipeline development, financial results, equity compensation, executive and board governance, auditor matters, and capital-structure information.
Stock Performance
Damora Therapeutics (DMRA) closed at $18.56 on October 13, 2026. Over the past month, the price has lost 34.0%.
DMRA Metrics & Rankings
Price returns through October 13, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Damora Therapeutics has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, clinical trial. View all DMRA news →
SEC Filings
Damora Therapeutics has filed 10 recent SEC filings, including 2 Form 4, 1 Form 3, 1 Form 144, 1 Form EFFECT. The most recent filing was submitted on September 28, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMRA SEC filings →
Insider Radar
Insider buying activity at Damora Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
operating income reached -$210.9M, and net income was -$209.8M. Diluted earnings per share stood at $3.98. The company generated -$6.7M in operating cash flow. The current ratio was 12.98, measuring current assets divided by current liabilities.
Upcoming Events
DMR-003 regulatory submission
DMR-003 submission
Initial clinical data
Proof-of-concept datasets begin
DMR-001 POC datasets begin
DMR-001 PoC datasets
Options fully vest
Options expiration
Options expiration
Option expiration date
Damora Therapeutics has 10 upcoming scheduled events. The next event, "DMR-003 regulatory submission", is scheduled for January 1, 2027 (in 78 days). 4 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the DMRA stock price.
Short Interest History
Short interest in Damora Therapeutics (DMRA) currently stands at 4.7 million shares, up 0.0% from the previous reporting period, representing 8.6% of the float. Since March 2026, short interest has increased by 1006.7%.
Days to Cover History
Days to cover for Damora Therapeutics (DMRA) currently stands at 4.8 days, down 43.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since March 2026, the figure has increased by 147.4%. Across the settlements charted above, it has ranged from 1.9 to 13.6 days.
DMRA Company Profile & Sector Positioning
Damora Therapeutics (DMRA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.